Proven Results with ILARIS

ILARIS® is a biologic medicine that is FDA approved to treat Cryopyrin-Associated Periodic Syndromes (CAPS), including FCAS and MWS in adults and children aged 4 years and older. This FDA approval was based on research that included 35 patients.

In a clinical study, ILARIS provided complete and lasting improvement from CAPS. Patients with CAPS were given ILARIS and evaluated for a complete response, which was measured by laboratory results and a doctor's evaluation of the patient's skin disease and symptoms being minimal or better, including symptoms such as:

Rash

Rash

Headache

Headache

Sore or red eyes

Sore or red eyes

Fatigue

Fatigue

Muscle and/or joint pain

Muscle and/or
joint pain

Within the first treatment period, ILARIS provided
a complete response from CAPS:

0%

97% of CAPS patients had a complete response after treatment within the first treatment period taking ILARIS

97% of patients had a complete response after treatment within the first treatment period (8 weeks)

Within the first treatment period, ILARIS provided a complete response from CAPS:

97% of CAPS patients had a complete response after treatment within the first treatment period taking ILARIS

97% of patients had a complete response after treatment within the first treatment period (8 weeks)

0%

71% of CAPS patients had a complete response to treatment in 7 days of taking ILARIS

The majority of patients (71%) experienced a complete response to treatment in 7 days

The majority of patients (71%) experienced a complete response to treatment in 7 days

The majority of patients had long-lasting improvement

In a clinical study, no patients experienced a flare of their CAPS symptoms over an 8-month period after 4 doses of ILARIS

In a clinical study, no patients experienced a flare of their symptoms over an 8-month period after 4 doses of ILARIS.

In a clinical study, no patients experienced a flare of their symptoms over an 8-month period after 4 doses of ILARIS.

A flare was measured by laboratory results and a doctor's evaluation of the patient's symptoms being mild or worse, or an evaluation of both the patient's symptoms and skin disease being minimal or worse.

Talk to a doctor about whether ILARIS may be right for your child.

Talk to a doctor about whether ILARIS may be right for your child.

Next: Safety Considerations